Current status of proteomics of soft tissue sarcomas

References

• Fletcher CDM, Bridge JA, Hogendoorn P, et al. WHO classification of tumours of soft tissue and bone. Geneva: WHO Press; 2013.
   Google Scholar
• Weiss SW, Goldblum JR. Soft tissue tumors. Lyon, France: Mosby; 2007.
   Google Scholar
• Van De Rijn M, Fletcher JA. Genetics of soft tissue tumors. Annu Rev Pathol. 2006;1:435–466.
   PubMed Web of Science ®Google Scholar
• Wardelmann E, Schildhaus HU, Merkelbach-Bruse S, et al. Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies. Ann Oncol. 2010;21(Suppl 7):vii265–269.
   PubMedGoogle Scholar
• Sethi TK, Keedy VL. Histology-specific uses of tyrosine kinase inhibitors in non-gastrointestinal stromal tumor sarcomas. Curr Treat Options Oncol. 2016;17(2):11.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–480.
   PubMed Web of Science ®Google Scholar
• Nishida T, Doi T, Naito Y. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Expert Opin Pharmacother. 2014;15(14):1979–1989.
   PubMed Web of Science ®Google Scholar
• Taylor BS, Barretina J, Maki RG, et al. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 2011;11(8):541–557.
   PubMed Web of Science ®Google Scholar
• Kansara M, Teng MW, Smyth MJ, et al. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14(11):722–735.
   PubMed Web of Science ®Google Scholar
• Gry M, Rimini R, Stromberg S, et al. Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics. 2009;10:365.
   PubMed Web of Science ®Google Scholar
• Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002;1(4):304–313.
   PubMed Web of Science ®Google Scholar
• Schwanhausser B, Busse D, Li N, et al. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337–342.
   PubMed Web of Science ®Google Scholar
• Tipton JD, Tran JC, Catherman AD, et al. Analysis of intact protein isoforms by mass spectrometry. J Biol Chem. 2011;286(29):25451–25458.
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Yamamoto S, Nojima T, et al. Validity and reproducibility of histologic diagnosis and grading for adult soft-tissue sarcomas. Hum Pathol. 2002;33(1):111–115.
   PubMed Web of Science ®Google Scholar
• Timms JF, Hale OJ, Cramer R. Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics. Expert Rev Proteomics. 2016;13(6):593–607.
   PubMed Web of Science ®Google Scholar
• Burnum KE, Frappier SL, Caprioli RM. Matrix-assisted laser desorption/ionization imaging mass spectrometry for the investigation of proteins and peptides. Annu Rev Anal Chem (Palo Alto Calif). 2008;1:689–705.
   PubMed Web of Science ®Google Scholar
• Chaurand P, Norris JL, Cornett DS, et al. New developments in profiling and imaging of proteins from tissue sections by MALDI mass spectrometry. J Proteome Res. 2006;5(11):2889–2900.
   PubMed Web of Science ®Google Scholar
• Cerruti CD, Benabdellah F, Laprevote O, et al. MALDI imaging and structural analysis of rat brain lipid negative ions with 9-aminoacridine matrix. Anal Chem. 2012;84(5):2164–2171.
   PubMed Web of Science ®Google Scholar
• Trim PJ, Henson CM, Avery JL, et al. Matrix-assisted laser desorption/ionization-ion mobility separation-mass spectrometry imaging of vinblastine in whole body tissue sections. Anal Chem. 2008;80(22):8628–8634.
   PubMed Web of Science ®Google Scholar
• Atkinson SJ, Loadman PM, Sutton C, et al. Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun Mass Spectrom. 2007;21(7):1271–1276.
   PubMed Web of Science ®Google Scholar
• Lou S, Balluff B, De Graaff MA, et al. High-grade sarcoma diagnosis and prognosis: biomarker discovery by mass spectrometry imaging. Proteomics. 2016;16(11–12):1802–1813.
   PubMed Web of Science ®Google Scholar
• Suehara Y, Kondo T, Fujii K, et al. Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas. Proteomics. 2006;6(15):4402–4409.
   PubMed Web of Science ®Google Scholar
• Stanta G, Bonin S, Machado I, et al. Models of biobanking and tissue preservation: RNA quality in archival samples in pathology laboratories and “in vivo biobanking” by tumor xenografts in nude mice-two models of quality assurance in pathology. Biopreserv Biobank. 2011;9(2):149–155.
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Liposarcoma EM. A clinicopathologic subtyping of 52 cases. Acta Pathol Jpn. 1982;32(6):933–948.
   PubMedGoogle Scholar
• Heijs B, Abdelmoula WM, Lou S, et al. Histology-guided high-resolution matrix-assisted laser desorption ionization mass spectrometry imaging. Anal Chem. 2015;87(24):11978–11983.
   PubMed Web of Science ®Google Scholar
• Cervi D, Yip TT, Bhattacharya N, et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood. 2008;111(3):1201–1207.
   PubMed Web of Science ®Google Scholar
• Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature. 1982;297(5864):307–312.
   PubMed Web of Science ®Google Scholar
• Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 1990;247(4938):77–79.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kindblom LG. Gastrointestinal stromal tumors – a review. Acta Orthop Scand Suppl. 2004;75(311):62–71.
   PubMedGoogle Scholar
• Miettinen M, El-Rifai W, L HLS, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002;33(5):478–483.
   PubMed Web of Science ®Google Scholar
• Rumessen JJ, Peters S, Thuneberg L. Light- and electron microscopical studies of interstitial cells of Cajal and muscle cells at the submucosal border of human colon. Lab Invest. 1993;68(4):481–495.
   PubMed Web of Science ®Google Scholar
• Zhong JH, Ma L, Li LQ, et al. Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems. Scand J Gastroenterol. 2011;46(6):645–651.
   PubMed Web of Science ®Google Scholar
• Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097–1104.
   PubMed Web of Science ®Google Scholar
• Blay JY, Von Mehren M, Blackstein ME. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer. 2010;116(22):5126–5137.
   PubMed Web of Science ®Google Scholar
• Berglund E, Dare E, Branca RM, et al. Secretome protein signature of human gastrointestinal stromal tumor cells. Exp Cell Res. 2015;336(1):158–170.
   PubMed Web of Science ®Google Scholar
• Suehara Y, Kondo T, Seki K, et al. Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res. 2008;14(6):1707–1717.
   PubMed Web of Science ®Google Scholar
• Resendes BL, Kuo SF, Robertson NG, et al. Isolation from cochlea of a novel human intronless gene with predominant fetal expression. J Assoc Res Otolaryngol. 2004;5(2):185–202.
   PubMed Web of Science ®Google Scholar
• Schwenk J, Metz M, Zolles G, et al. Native GABA(B) receptors are heteromultimers with a family of auxiliary subunits. Nature. 2010;465(7295):231–235.
   PubMed Web of Science ®Google Scholar
• Kikuta K, Gotoh M, Kanda T, et al. Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities. Jpn J Clin Oncol. 2010;40(1):60–72.
   PubMed Web of Science ®Google Scholar
• Kubota D, Orita H, Yoshida A, et al. Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities. Jpn J Clin Oncol. 2011.
   Web of Science ®Google Scholar
• Kikuta K, Kubota D, Saito T, et al. Clinical proteomics identified ATP-dependent RNA helicase DDX39 as a novel biomarker to predict poor prognosis of patients with gastrointestinal stromal tumor. J Proteomics. 2012;75(4):1089-1098.
   Web of Science ®Google Scholar
• Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol. 1999;23(1):82–87.
   PubMed Web of Science ®Google Scholar
• Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459–465.
   PubMed Web of Science ®Google Scholar
• Ichikawa H, Yoshida A, Kanda K, et al. Prognostic significance of PML expression in gastrointestinal stromal tumor; integrated proteomic and transcriptomic analysis. Cancer Sci. 2014;106(1):115–124.
   PubMed Web of Science ®Google Scholar
• Suehara Y, Kikuta K, Nakayama R, et al. Anatomic site-specific proteomic signatures of gastrointestinal stromal tumors. Proteomics Clin Appl. 2009;3(5):584–596.
   Web of Science ®Google Scholar
• Hashimoto H, Daimaru Y, Tsuneyoshi M, et al. Leiomyosarcoma of the external soft tissues. A clinicopathologic, immunohistochemical, and electron microscopic study. Cancer. 1986;57(10):2077–2088.
   PubMed Web of Science ®Google Scholar
• Mankin HJ, Casas-Ganem J, Kim JI, et al. Leiomyosarcoma of somatic soft tissues. Clin Orthop Relat Res. 2004;(421):225–231.
   PubMed Web of Science ®Google Scholar
• Gordon EM, Sankhala KK, Chawla N, et al. Trabectedin for soft tissue sarcoma: current status and future perspectives. Adv Ther. 2016;33(7):1055–1071.
   PubMed Web of Science ®Google Scholar
• Yoo KH, Kim HS, Lee SJ, et al. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer. 2015;15:154.
   PubMed Web of Science ®Google Scholar
• Kirik U, Hansson K, Krogh M, et al. Discovery-based protein expression profiling identifies distinct subgroups and pathways in leiomyosarcomas. Mol Cancer Res. 2014;12(12):1729–1739.
   PubMed Web of Science ®Google Scholar
• May EW, Lin ST, Lin CC, et al. Identification of up- and down-regulated proteins in doxorubicin-resistant uterine cancer cells: reticulocalbin-1 plays a key role in the development of doxorubicin-associated resistance. Pharmacol Res. 2014;90:1–17.
   PubMed Web of Science ®Google Scholar
• Yang J, Eddy JA, Pan Y, et al. Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug. Mol Cell Proteomics. 2010;9(11):2405–2413.
   PubMed Web of Science ®Google Scholar
• Abraham SC. Distinguishing gastrointestinal stromal tumors from their mimics: an update. Adv Anat Pathol. 2007;14(3):178–188.
   PubMed Web of Science ®Google Scholar
• Wells A, Yates C, Shepard CR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis. 2008;25(6):621–628.
   PubMed Web of Science ®Google Scholar
• Dhingra S, Rodriguez ME, Shen Q, et al. Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications. Int J Clin Exp Pathol. 2011;4(2):134–146.
   Web of Science ®Google Scholar
• Dagher R, Helman L. Rhabdomyosarcoma: an overview. Oncologist. 1999;4(1):34–44.
   PubMedGoogle Scholar
• Merlino G, Helman LJ. Rhabdomyosarcoma – working out the pathways. Oncogene. 1999;18(38):5340–5348.
   PubMed Web of Science ®Google Scholar
• Spunt SL, Smith LM, Ruymann FB, et al. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children’s oncology group. Clin Cancer Res. 2004;10(18 Pt 1):6072–6079.
   PubMed Web of Science ®Google Scholar
• Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19(12):3091–3102.
   PubMed Web of Science ®Google Scholar
• Pressey JG, Pressey CS, Robinson G, et al. 2D-difference gel electrophoretic proteomic analysis of a cell culture model of alveolar rhabdomyosarcoma. J Proteome Res. 2011;10(2):624–636.
   PubMed Web of Science ®Google Scholar
• Petricoin EF 3rd, Espina V, Araujo RP, et al. Phosphoprotein pathway mapping: akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007;67(7):3431–3440.
   PubMed Web of Science ®Google Scholar
• Spillane AJ, A’Hern R, Judson IR, et al. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000;18(22):3794–3803.
   PubMed Web of Science ®Google Scholar
• Clark J, Rocques PJ, Crew AJ, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet. 1994;7(4):502–508.
   PubMed Web of Science ®Google Scholar
• Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med. 1998;338(3):153–160.
   PubMed Web of Science ®Google Scholar
• Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol. 2004;22(20):4040–4050.
   PubMed Web of Science ®Google Scholar
• Trassard M, Le Doussal V, Hacene K, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001;19(2):525–534.
   PubMed Web of Science ®Google Scholar
• Su L, Sampaio AV, Jones KB, et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell. 2012;21(3):333–347.
   PubMed Web of Science ®Google Scholar
• Suehara Y, Tochigi N, Kubota D, et al. Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics. J Proteomics. 2011;74(6):829–842.
   PubMed Web of Science ®Google Scholar
• Suehara Y, Kikuta K, Nakayama R, et al. GST-P1 as a histological biomarker of synovial sarcoma revealed by proteomics. Proteomics Clin Appl. 2009;3(5):623–634.
   Web of Science ®Google Scholar
• Enzinger FM. Clear-cell sarcoma of tendons and aponeuroses. An analysis of 21 cases. Cancer. 1965;18:1163–1174.
   PubMed Web of Science ®Google Scholar
• Zucman J, Delattre O, Desmaze C, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet. 1993;4(4):341–345.
   PubMed Web of Science ®Google Scholar
• Chung EB, Enzinger FM. Malignant melanoma of soft parts. A reassessment of clear cell sarcoma. Am J Surg Pathol. 1983;7(5):405–413.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Semin Oncol. 2007;34(6):532–545.
   PubMed Web of Science ®Google Scholar
• Kawai A, Hosono A, Nakayama R, et al. Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients. Cancer. 2007;109(1):109–116.
   PubMed Web of Science ®Google Scholar
• Townsend EC, Murakami MA, Christodoulou A, et al. The public repository of xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell. 2016;30(1):183.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Paz K, Schwartz GK, et al. Patient-derived xenografts for individualized care in advanced sarcoma. Cancer. 2014;120(13):2006–2015.
   PubMed Web of Science ®Google Scholar
• Celis A, Rasmussen HH, Celis P, et al. Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis. 1999;20(2):355–361.
   PubMed Web of Science ®Google Scholar
• Dimas K, Tsimplouli C, Anagnostopoulos AK, et al. The proteome profile of two cell lines and their xenografts isolated from a patient with clear cell sarcoma (soft tissue melanoma). Cancer Genomics Proteomics. 2008;5(3–4):175–237.
   PubMedGoogle Scholar
• Weiss SW, Goldblum JR. Malignant soft tissue tumors of uncertain type. Enzinger and Weiss’s soft tissue tumors. Philadelphia, PA: Elsevier Mosby; 2008.
   Google Scholar
• Ordonez NG. Alveolar soft part sarcoma: a review and update. Adv Anat Pathol. 1999;6(3):125–139.
   PubMed Web of Science ®Google Scholar
• Tsuji K, Ishikawa Y, Imamura T. Technique for differentiating alveolar soft part sarcoma from other tumors in paraffin-embedded tissue: comparison of immunohistochemistry for TFE3 and CD147 and of reverse transcription polymerase chain reaction for ASPSCR1-TFE3 fusion transcript. Hum Pathol. 2012;43(3):356-363.
   Web of Science ®Google Scholar
• Kubota D, Yoshida A, Kawai A, et al. Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma. J Proteome Res. 2014;13(5):2250–2261.
   PubMed Web of Science ®Google Scholar
• Balgley BM, Guo T, Zhao K, et al. Evaluation of archival time on shotgun proteomics of formalin-fixed and paraffin-embedded tissues. J Proteome Res. 2009;8(2):917–925.
   PubMed Web of Science ®Google Scholar
• Haglund KE, Raut CP, Nascimento AF, et al. Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys. 2012;82(1):361–367.
   PubMed Web of Science ®Google Scholar
• Sanfilippo R, Miceli R, Grosso F, et al. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2011;18(3):720–725.
   PubMed Web of Science ®Google Scholar
• Mentzel T, Calonje E, Wadden C, et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol. 1996;20(4):391–405.
   PubMed Web of Science ®Google Scholar
• Merck C, Angervall L, Kindblom LG, et al. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta pathologica, microbiologica, et immunologica Scandinavica. Supplement. 1983;282:1–40.
   Google Scholar
• Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977;39(4):1672–1685.
   PubMed Web of Science ®Google Scholar
• Willems SM, Debiec-Rychter M, Szuhai K, et al. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol. 2006;19(3):407–416.
   PubMed Web of Science ®Google Scholar
• Lin CN, Chou SC, Li CF, et al. Prognostic factors of myxofibrosarcomas: implications of margin status, tumor necrosis, and mitotic rate on survival. J Surg Oncol. 2006;93(4):294–303.
   PubMed Web of Science ®Google Scholar
• Kindblom LG, Merck C, Angervall L. The ultrastructure of myxofibrosarcoma. A study of 11 cases.Virchows Arch A Pathol Anat Histol. 1979;381(2):121–139.
   Google Scholar
• Manoso MW, Pratt J, Healey JH, et al. Infiltrative MRI pattern and incomplete initial surgery compromise local control of myxofibrosarcoma. Clin Orthop Relat Res. 2006;450:89–94.
   PubMed Web of Science ®Google Scholar
• Huang HY, Lal P, Qin J, et al. Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol. 2004;35(5):612–621.
   PubMed Web of Science ®Google Scholar
• Kikuta K, Kubota D, Yoshida A, et al. An analysis of factors related to the tail-like pattern of myxofibrosarcoma seen on MRI. Skeletal Radiol. 2015;44(1):55–62.
   PubMed Web of Science ®Google Scholar
• Kikuta K, Kubota D, Yoshida A, et al. Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) is a novel biomarker of myxofibrosarcoma invasion identified by global protein expression profiling. Biochim Biophys Acta. 2017;1865(9):1160–1166.
   PubMedGoogle Scholar
• Feng H, Lopez GY, Kim CK, et al. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest. 2014;124(9):3741–3756.
   PubMed Web of Science ®Google Scholar
• Kondo T. Cancer proteome-expression database: genome medicine database of Japan proteomics. Expert Rev Proteomics. 2010;7(1):21–27.
   PubMed Web of Science ®Google Scholar
• Taylor CF, Paton NW, Lilley KS, et al. The minimum information about a proteomics experiment (MIAPE). Nat Biotechnol. 2007;25(8):887–893.
   PubMed Web of Science ®Google Scholar
• Pan X, Yoshida A, Kawai A, et al. Current status of publicly available sarcoma cell lines for use in proteomic studies. Expert Rev Proteomics. 2016;13(2):227–240.
   PubMed Web of Science ®Google Scholar
• Thul PJ, Akesson L, Wiking M, et al. A subcellular map of the human proteome. Science. 2017;356:6340.
   Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.
   PubMed Web of Science ®Google Scholar
• Sheynkman GM, Shortreed MR, Cesnik AJ, et al. Proteogenomics: integrating next-generation sequencing and mass spectrometry to characterize human proteomic variation. Annu Rev Anal Chem (Palo Alto Calif). 2016;9(1):521–545.
   PubMed Web of Science ®Google Scholar
• Byrne AT, Alferez DG, Amant F, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer. 2017;17(4):254–268.
   PubMed Web of Science ®Google Scholar
• Billingham L, Malottki K, Steven N. Research methods to change clinical practice for patients with rare cancers. Lancet Oncol. 2016;17(2):e70–e80.
   PubMed Web of Science ®Google Scholar
• Ghosn M, El Rassy E, Kourie HR. Immunotherapies in sarcoma: updates and future perspectives. World J Clin Oncol. 2017;8(2):145–150.
   PubMedGoogle Scholar
• Khodadoust MS, Olsson N, Wagar LE, et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature. 2017;543(7647):723–727.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang J, Wang X, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014;513(7518):382–387.
   PubMed Web of Science ®Google Scholar
• Mertins P, Mani DR, Ruggles KV, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534(7605):55–62.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu T, Zhang Z, et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell. 2016;166(3):755–765.
   PubMed Web of Science ®Google Scholar
• Rivers RC, Kinsinger C, Boja ES, et al. Linking cancer genome to proteome: NCI’s investment into proteogenomics. Proteomics. 2014;14(23–24):2633–2636.
   PubMed Web of Science ®Google Scholar
• Oyama R, Takahashi M, Yoshida A, et al. Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines. Sci Rep. 2017;7(1):4712.
   PubMedGoogle Scholar
• Bairoch A. The Cellosaurus: a cell line knowledge resource. http://web.expasy.org/cellosaurus/
   Google Scholar
• Andersson K, Bray F, Arbyn M, et al. The interface of population-based cancer registries and biobanks in etiological and clinical research – current and future perspectives. Acta Oncol. 2010;49(8):1227–1234.
   PubMed Web of Science ®Google Scholar
• Tupasela A, Stephens N. The boom and bust cycle of biobanking - thinking through the life cycle of biobanks. Croat Med J. 2013;54(5):501–503.
   PubMed Web of Science ®Google Scholar
• Cadigan RJ, Lassiter D, Haldeman K, et al. Neglected ethical issues in biobank management: results from a U.S. study. Life Sci Soc Policy. 2013;9(1):1.
   PubMedGoogle Scholar
• Bledsoe MJ. Ethical legal and social issues of biobanking: past, present, and future. Biopreserv Biobank. 2017;15(2):142–147.
   PubMed Web of Science ®Google Scholar